Targeting the Yin and Yang of KRASG12C
- PMID: 40185675
- DOI: 10.1016/j.molmed.2025.03.007
Targeting the Yin and Yang of KRASG12C
Abstract
In a recent study in Cancer Discovery, Maciag et al. introduce BBO-8520, a novel inhibitor targeting both the active and inactive states of KRASG12C. This dual inhibition shows superior target engagement and prolonged tumor suppression, offering a compelling strategy to overcome resistance development and improve outcomes in KRASG12C-mutant cancers.
Keywords: KRAS(G12C); MAPK signaling; covalent inhibitor; dual inhibition.
Copyright © 2025 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no conflicts of interest.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
